Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
481.7 USD | -0.29% | +2.45% | +18.38% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.11 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.38% | 125B | B+ | ||
+13.74% | 108B | B+ | ||
-7.28% | 24.21B | B+ | ||
+2.07% | 22.78B | B | ||
-10.79% | 17.96B | A- | ||
-41.74% | 16.43B | A- | ||
-13.23% | 16.37B | B | ||
+1.61% | 13.58B | C+ | ||
+27.95% | 11.66B | C+ | ||
+90.63% | 9.17B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VRTX Stock
- Ratings Vertex Pharmaceuticals Incorporated